Intrahepatic Cholangiocarcinoma Market Report 2032: Epidemiology, Therapies, Latest FDA, EMA, Approvals by DelveInsight
Intrahepatic Cholangiocarcinoma Market is expected to grow at a significant CAGR, asserts DelveInsight.
LAS VEGAS, NEVADA, UNITED STATES, April 1, 2024 /EINPresswire.com/ -- DelveInsight’s “Intrahepatic Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Intrahepatic Cholangiocarcinoma, historical and forecasted epidemiology as well as the Intrahepatic Cholangiocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Intrahepatic Cholangiocarcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intrahepatic Cholangiocarcinoma Market Forecast
Some of the key facts of the Intrahepatic Cholangiocarcinoma Market Report:
The Intrahepatic Cholangiocarcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma being developed by Tyra Biosciences. TYRA remains on track to submit an IND with the US FDA TYRA-200 in the second half of 2022.
In September 2021, Knight Therapeutics entered into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply to Knight of tafasitamab and pemigatinib, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America.
In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.
In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trial in China.
Relay Therapeutics announced the initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008, an FGFR2-altered intrahepatic cholangiocarcinomain January 2022.
In May 2021, Kinnate Biopharma Inc. Closes USD 35 Million Series A Financing to Establish a Chinese Joint Venture. The joint venture will pursue the development of KIN-3248 for the Chinese market. KIN-3248 is a Fibroblast Growth Factor Receptors (FGFR) inhibitor candidate for the treatment of patients with intrahepatic cholangiocarcinoma (ICC).
The Investigational New Drug application for KIN-3248 was cleared by the US FDA on January 18, 2022, and Kinnate anticipates the initiation of a Phase I trial of KIN-3248 in the first half of 2022.
In 2022, Basilea will continue its activities in oncology in order to ensure project continuity and progression. For derazantinib, the company will focus on continuing the FIDES-01 study in intrahepatic cholangiocarcinoma (iCCA).
In 2022, out of the total diagnosed incident cases of Cholangiocarcinoma ~11,500 cases were of Intrahepatic in the 7MM.
In 2022, the diagnosed incident cases of Cholangiocarcinoma in Japan were found to be ~16,700 among which total iCCA cases were ~8,900.
According to Sinn et al. (2021), the incidence rate of iCCA was found to be 1.6 and 2.8 per 100,000 in women and men, respectively.
As per the study of Saha et al. (2016), the median age at diagnosis was younger for iCCA for each 5-year period dating back to 1973. The percentage of patients diagnosed with iCCA within the indicated age range was shown as 10%, 17%, 25%, 28%, and 20% in iCCA for less than 50 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and over, respectively.
Key Intrahepatic Cholangiocarcinoma Companies: Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, Qed Therapeutics, Janssen Pharmaceutical, Taiho Oncology, Redhill Biopharma, Glaxosmithkline, Merck/Glaxosmithkline, Eisai, Taiho
Pharmaceutical/Servier, Bayer, Sorrento Therapeutics/Yuhan Corporation, Hutchison Medipharma, Jiangsu Hengrui Medicine, Astrazeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array Biopharmas, and others
Key Intrahepatic Cholangiocarcinoma Therapies: Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others
The Intrahepatic Cholangiocarcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Intrahepatic Cholangiocarcinoma pipeline products will significantly revolutionize the Intrahepatic Cholangiocarcinoma market dynamics.
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent cancer originating in the liver, accounting for approximately 10% of all cholangiocarcinomas. It arises from the bile ducts located within the liver parenchyma, specifically proximal to the secondary biliary radicals. Histologically, the majority of ICCs manifest as adenocarcinomas, typically well-differentiated. The development of ICC is often attributed to mutations in the KRAS oncogene, which regulates cell proliferation, in conjunction with the deletion of the p53 tumor suppressor gene. The American Joint Committee on Cancer (AJCC) TNM staging system, currently in its seventh edition, is widely used to assess the progression and resectability of ICC, comprising four stages.
Intrahepatic Cholangiocarcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Intrahepatic Cholangiocarcinoma Epidemiology Segmentation:
The Intrahepatic Cholangiocarcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Intrahepatic Cholangiocarcinoma
Prevalent Cases of Intrahepatic Cholangiocarcinoma by severity
Gender-specific Prevalence of Intrahepatic Cholangiocarcinoma
Diagnosed Cases of Episodic and Chronic Intrahepatic Cholangiocarcinoma
Download the report to understand which factors are driving Intrahepatic Cholangiocarcinoma epidemiology trends @ Intrahepatic Cholangiocarcinoma Epidemiology Forecast
Intrahepatic Cholangiocarcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intrahepatic Cholangiocarcinoma market or expected to get launched during the study period. The analysis covers Intrahepatic Cholangiocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Intrahepatic Cholangiocarcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Intrahepatic Cholangiocarcinoma Therapies
Derazantinib
VG161
SD 101
FT-2102
KIN-3248
RLY-4008
TYR-200
HMPL-453
Opaganib
XmAb®22841
STP705,
Camrelizumab
Embrace™ Hydrogel Embolic System
CTX-009
Intrahepatic Cholangiocarcinoma Key Companies
Incyte Corporation
Roche
Delcath Systems
Basilea Pharmaceutica
Agios Pharmaceuticals
Bayer
Loxo Oncology
Bayer
Qed Therapeutics
Janssen Pharmaceutical
Taiho Oncology
Redhill Biopharma
Glaxosmithkline
Merck
Glaxosmithkline
Eisai
Taiho Pharmaceutical
Servier, Bayer
Sorrento Therapeutics
Yuhan Corporation
Hutchison Medipharma
Jiangsu Hengrui Medicine
Astrazeneca
Eli Lilly
Servier Laboratories
Genoscience Pharma
Forma Therapeutics
Array Biopharmas
Discover more about therapies set to grab major Intrahepatic Cholangiocarcinoma market share @ Intrahepatic Cholangiocarcinoma Treatment Landscape
Scope of the Intrahepatic Cholangiocarcinoma Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Intrahepatic Cholangiocarcinoma Companies: Incyte Corporation, Roche, Delcath Systems, Basilea Pharmaceutica, Agios Pharmaceuticals, Bayer, Loxo Oncology/Bayer, Qed Therapeutics, Janssen Pharmaceutical, Taiho Oncology, Redhill Biopharma, Glaxosmithkline, Merck/Glaxosmithkline, Eisai, Taiho
Pharmaceutical/Servier, Bayer, Sorrento Therapeutics/Yuhan Corporation, Hutchison Medipharma, Jiangsu Hengrui Medicine, Astrazeneca, Eli Lilly, Servier Laboratories, Genoscience Pharma, Forma Therapeutics, Array Biopharmas, and others
Key Intrahepatic Cholangiocarcinoma Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others
Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Intrahepatic Cholangiocarcinoma Unmet Needs, KOL’s views, Analyst’s views, Intrahepatic Cholangiocarcinoma Market Access and Reimbursement
Table of Contents
1. Intrahepatic Cholangiocarcinoma Market Report Introduction
2. Executive Summary for Intrahepatic Cholangiocarcinoma
3. SWOT analysis of Intrahepatic Cholangiocarcinoma
4. Intrahepatic Cholangiocarcinoma Patient Share (%) Overview at a Glance
5. Intrahepatic Cholangiocarcinoma Market Overview at a Glance
6. Intrahepatic Cholangiocarcinoma Disease Background and Overview
7. Intrahepatic Cholangiocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Intrahepatic Cholangiocarcinoma
9. Intrahepatic Cholangiocarcinoma Current Treatment and Medical Practices
10. Intrahepatic Cholangiocarcinoma Unmet Needs
11. Intrahepatic Cholangiocarcinoma Emerging Therapies
12. Intrahepatic Cholangiocarcinoma Market Outlook
13. Country-Wise Intrahepatic Cholangiocarcinoma Market Analysis (2019–2032)
14. Intrahepatic Cholangiocarcinoma Market Access and Reimbursement of Therapies
15. Intrahepatic Cholangiocarcinoma Market Drivers
16. Intrahepatic Cholangiocarcinoma Market Barriers
17. Intrahepatic Cholangiocarcinoma Appendix
18. Intrahepatic Cholangiocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Intrahepatic Cholangiocarcinoma Pipeline
"Intrahepatic Cholangiocarcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Intrahepatic Cholangiocarcinoma market. A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided, which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines.
Intrahepatic Cholangiocarcinoma Epidemiology
DelveInsight's 'Intrahepatic Cholangiocarcinoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Intrahepatic Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
